Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Trabectedin (Primary) ; Carboplatin; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms INOVATYON
- 16 Jul 2018 Planned End Date changed from 1 Dec 2019 to 1 Jul 2020.
- 16 Jul 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Jul 2020.
- 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.